NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on cancer therapies, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The presentation is scheduled for Monday, September 8th, at 4:00 pm ET.
Investors can access the live audio webcast through the Investors section of NextCure's website. A replay will be available for 30 days following the event.
NextCure (Nasdaq: NXTC), societ脿 biofarmaceutica in fase clinica focalizzata sulle terapie oncologiche, parteciper脿 a una conversazione informale (fireside chat) durante la H.C. Wainwright 27th Annual Global Investment Conference a New York City. La presentazione 猫 prevista per luned矛 8 settembre alle 16:00 ET.
Gli investitori potranno seguire la diretta audio in streaming nella sezione Investors del sito di NextCure. Una registrazione-replay sar脿 disponibile per 30 giorni dopo l'evento.
NextCure (Nasdaq: NXTC), una compa帽铆a biofarmac茅utica en fase cl铆nica centrada en terapias contra el c谩ncer, participar谩 en un fireside chat en la H.C. Wainwright 27th Annual Global Investment Conference en Nueva York. La presentaci贸n est谩 programada para el lunes 8 de septiembre a las 4:00 p.m. ET.
Los inversores podr谩n acceder a la retransmisi贸n de audio en directo a trav茅s de la secci贸n Investors del sitio web de NextCure. La repetici贸n estar谩 disponible durante 30 d铆as despu茅s del evento.
NextCure (Nasdaq: NXTC)電� 頃晹 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎届偓搿�, 雺挫殨鞐愳劀 鞐措Μ電� H.C. Wainwright 27th Annual Global Investment Conference鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃╇媹雼�. 氚滍憸電� 9鞗� 8鞚� 鞗旍殧鞚� 鞓ろ泟 4鞁�(霃欕秬鞁滉皠)搿� 鞓堨爼霅橃柎 鞛堨姷雼堧嫟.
韴瀽鞛愲摛鞚� NextCure 鞗轨偓鞚错姼鞚� Investors 靹轨厴鞚� 韱淀暣 霛检澊敫� 鞓る敂鞓� 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 鞚措菠韸� 膦呺 頉� 30鞚� 霃欖晥 鞛嫓觳澊 臧�電ロ暕雼堧嫟.
NextCure (Nasdaq: NXTC), une soci茅t茅 biopharmaceutique en phase clinique ax茅e sur les th茅rapies contre le cancer, participera 脿 une discussion informelle (fireside chat) lors de la H.C. Wainwright 27th Annual Global Investment Conference 脿 New York. La pr茅sentation est pr茅vue le lundi 8 septembre 脿 16h00 ET.
Les investisseurs pourront acc茅der au webcast audio en direct via la section Investors du site de NextCure. Une rediffusion sera disponible pendant 30 jours apr猫s l'茅v茅nement.
NextCure (Nasdaq: NXTC), ein biopharmazeutisches Unternehmen in klinischer Phase mit Fokus auf Krebsbehandlungen, wird an einem Fireside-Chat auf der H.C. Wainwright 27th Annual Global Investment Conference in New York City teilnehmen. Die Pr盲sentation ist f眉r Montag, den 8. September, um 16:00 Uhr ET angesetzt.
Investoren k枚nnen den Live-Audio-Webcast 眉ber den Investors-Bereich der NextCure-Website verfolgen. Eine Aufzeichnung wird 30 Tage nach der Veranstaltung verf眉gbar sein.
- None.
- None.
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on Monday, September 8th, at 4:00 pm ET.
A live audio webcast will be available through the Investors section of the company鈥檚 website at . A replay of the webcast will be available after the event and archived on the website for 30 days.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Please visit for more information.
Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as 鈥渆xpects,鈥� 鈥渂elieves,鈥� 鈥渋ntends,鈥� 鈥渉ope,鈥� 鈥渇orward鈥� and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure鈥檚 plans, objectives and intentions with respect to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our discovery platform. More detailed information on these and additional factors that could affect NextCure鈥檚 actual results are described in NextCure鈥檚 filings with the Securities and Exchange Commission (the 鈥淪EC鈥�), including NextCure鈥檚 most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
FAQ
When is NextCure (NXTC) presenting at the H.C. Wainwright Conference?
How can investors access NextCure's (NXTC) H.C. Wainwright Conference presentation?
How long will NextCure's (NXTC) conference presentation replay be available?
What type of company is NextCure (NXTC)?
